Physician profile
Calvin R Schaerer, JR.
NPI 1427046234
$1,546.10
in general payments reported to CMS, 2019-2025
11 companies · $244 in 2025
The $244 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $16.64 · 2021: $140 · 2022: $313 · 2023: $314 · 2024: $344 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $565.58 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $196.71 | 2021-2024 | Bexsero, Pediarix, Menveo |
| Pfizer INC. | $174.26 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $170.39 | 2025 | Jornay Pm |
| Seqirus USA INC | $104.57 | 2021-2023 | Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $91.32 | 2019-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Tris Pharma INC | $79.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.70 | 2019-2021 | |
| Sanofi Pasteur INC. | $45.81 | 2019-2021 | |
| Neurelis, INC. | $23.82 | 2022 | |
| Genentech USA, INC. | $22.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Schaerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.